Novartis Partners with Gene Editing Co to Boost R&D

Nov. 13, 2017

Novartis has entered into a research and development collaboration with Homology Medicines, a genetic medicines company, to develop new treatments for select ophthalmic targets.

In addition to making an upfront payment and equity investment, Novartis will provide funding to advance current programs and to explore new opportunities using the Massachusetts-based startup’s technology platform.

According to Novartis, the collaboration is designed to accelerate an initiative at Novartis Institutes for BioMedical Research (NIBR) that engages researchers across the company who are involved in projects with a common denominator: the genetic reprogramming of cells. Homology’s adeno-associated viruses (AAV) technology may aid their work. 

Read the press release
Read the Novartis article